Erschienen in:
01.08.2011 | Dementias - Short Communication
Memantine in moderate to severe Alzheimer’s disease: an observational post-marketing study
verfasst von:
Michael Rainer, A. Wuschitz, C. Jagsch, C. Erb, J.-J. Chirikdjian, H. A. M. Mucke
Erschienen in:
Journal of Neural Transmission
|
Ausgabe 8/2011
Einloggen, um Zugang zu erhalten
Abstract
Memantine is an N-methyl-d-aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer’s disease (AD). We conducted a 4-month observational, post-marketing, Austrian study of memantine in 377 outpatients with moderate to severe AD. In this ‘real-life’ setting, memantine was well-tolerated, and produced benefits in cognition (Mini-Mental State Examination), activities of daily living (Activities of Daily Living score), and global function (Clinical Global Impression scale). Treatment effects were apparent in both pre-treated and treatment-naïve patient subgroups.